The following are archived listings from the DMHA Grant and Funding Opportunity page hosted by Prevention Insights. When opportunities have expired (e.g., submission dates have passed), they will be moved to this list. The most current grant and funding listings can be found on the DMHA Grant and Funding Opportunities page.
(List last updated on January 16, 2025)
DFC Support Program – National Community Anti-Drug Coalition Institute (NCI)
https://www.grants.gov/search-results-detail/355995
NCI-NCI-24-001
National Community Anti-Drug Coalition Institute (NCI)
Current
Grant
$2,500,000 per year
One
September 16,2024
September 1, 2024 to August 31, 2025
The award will support the primary goals of the NCI, which are to: 1) increase the percentage of community coalitions across the United States that are effective in their work; and 2) strengthen technical assistance and training to community coalitions throughout the United States and territories.
ONDCP encourages applications from any national nonprofit organization that represents, provides technical assistance and training to, and has special expertise and broad, national-level experience in community anti-drug coalitions under section 1032 of the National Narcotics Leadership Act of 1988 (21 U.S.C. 1532). See Public Law 115-271, 132 Stat. 4112 § 8204 (codified as amended at Subsection “(b) Eligible Organizations” in 21 U.S.C. 1521 Note).
Types of eligible organizations:
DoD Alcohol and Substance Use Disorders, Consortium Award
https://www.grants.gov/search-results-detail/355004
HT942524ASUDRPCA
Deptartment of the Army – USAMRAA
Current
Cooperative agreement
$11,525,000
September 24, 2024
The FY24 ASUDRP CA supports the establishment of a Consortium whose purpose is to identify, evaluate, and advance pharmacotherapies for alcohol, opioid, and other substance use disorders, with an emphasis on other co-occurring mental health conditions, through rigorous, collaborative research efforts that translate basic knowledge and early-stage clinical products into evidence-based treatments. The goal of this research is to maximize functioning and quality of life for Service Members, their Families, Veterans, and the American public.
The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public.
Each individual organization must apply to this program announcement as a Consortium Management Core (CMC) by means of a single application, and may also serve as a future research and/or trial site. The CMC will be responsible for coordinating with the Consortium Steering Committee (CSC) and Consortium Executive Committee (CEC) to prioritize, propose, conduct, and analyze basic research and clinical trials, and developing a roadmap to translate basic science knowledge into evidence-based treatments for ASUD. Clinical trials that include military and Veteran populations are encouraged.
Applications may be submitted by foreign or domestic extramural organizations and intramural Department of Defense (DOD) organizations, defined as follows:
Ending the HIV Epidemic in the U.S. – Ryan White HIV/AIDS Program Parts A and B
https://www.hrsa.gov/grants/find-funding/HRSA-25-063
HRSA-25-063
Health Resources & Services Administration (HRSA)
Current
Cooperative agreement
$2,200,000 to $30,200,000
47
October 22, 2024
February 1, 2025
March 1, 2025 to February 28, 2030
The purpose of this initiative is to focus resources in 48 counties, Washington, D.C., San Juan, Puerto Rico (PR), and seven states with the highest incidence or burden of HIV to implement effective and innovative strategies, interventions, approaches, and services to reduce new HIV infections in the United States. The Ending the HIV Epidemic in the U.S. (hereafter referred to as the “EHE initiative”) focuses on four key strategies:
HRSA and the Centers for Disease Control and Prevention (CDC), along with the National Institutes of Health (NIH) Centers for AIDS Research (CFARs), the Indian Health Service (IHS), Department of Housing and Urban Development (HUD), and the Substance Abuse and Mental Health Services Administration (SAMHSA) are collaborating on implementation of these key strategies. HRSA's responsibilities include increasing testing and prevention among Health Center Program patients, providing access to HIV care and treatment through the RWHAP and Health Center Program, and linking people with HIV, newly diagnosed or re-identified through testing programs, to care, and responding to outbreaks. For the Ryan White Program, the EHE initiative expands the program's ability to meet the needs of clients, specifically focusing on linking people with HIV who are either newly diagnosed, diagnosed but currently not in care, or are diagnosed and in care but not yet virally suppressed, to the essential HIV care, treatment, and support services needed to help them reach viral suppression.
Ending the HIV Epidemic in the U.S. – Technical Assistance Provider
https://www.hrsa.gov/grants/find-funding/HRSA-25-064
HRSA-25-064
Health Resources & Services Administration (HRSA)
Current
Cooperative agreement
$2,000,000
Five
October 22, 2024
February 1, 2025
March 1, 2025, to February 28, 2030 (awarded in five 12-month budget periods)
The overall purpose of this notice of funding opportunity is to undertake a series of activities to support the recipients of Ending the HIV Epidemic in the U.S. – Ryan White HIV/AIDS Program Parts A and B (HRSA-25-063) in meeting the goals of the Ending the HIV Epidemic in the U.S. (hereafter referred to as the “EHE initiative”). The EHE initiative has four key strategies:
The Technical Assistance Provider (HRSA-25-064) is responsible for providing technical assistance (TA) to the recipients of HRSA-25-063 on implementation of work plan activities, innovative approaches, and interventions.
HRSA will fund one organization under each announcement to ensure effectiveness and efficiency in the implementation of activities by HRSA-25-063 recipients to support treatment and response activities of the EHE initiative. The intent of the funding opportunity is to maximize the success in developing, implementing, coordinating, and integrating strategies, interventions, approaches, and services to achieve the goals of the EHE initiative. HRSA expects that the recipient(s) of these awards will collaborate to support the recipients of HRSA-25-063. You must apply to the correct announcement number (HRSA-25-064 or HRSA-25-065) that corresponds to the stated activities listed in this section. If you are applying for both announcement numbers, you must submit a separate application for each.
Who can apply:
Types of eligible organizations:
These types of domestic organizations may apply. “Domestic” means the 50 states, the District of Columbia, the Commonwealth of Puerto Rico, the Northern Mariana Islands, American Samoa, Guam, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of the Marshall Islands, or the Republic of Palau.
Effectiveness Research to Prevent Polysubstance-Impaired Driving
https://apply07.grants.gov/apply/opportunities/instructions/PKG00287806-instructions.pdf
RFA-CE-25-028
Centers for Disease Control and Prevention NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL
Current
Cooperative agreement
First budget period (September 30, 2025 to September 29, 2026): $350,000
Total period of performance (September 30, 2025 to September 29, 2028): $1,050,000
One (FY 2025)
Letter of Intent: November 1, 2024
Application: December 2, 2024
Pending award date
First budget period: September 30, 2025 to September 29, 2026
The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research to rigorously evaluate and examine effectiveness of strategies, programs, or policies (collectively referred to as “strategies”) for preventing polysubstance-impaired driving and associated crashes, nonfatal injuries, or deaths. Polysubstance-impaired driving means driving while impaired by two or more substances, such as alcohol and opioids or cannabis and alcohol. Comprehensive evaluations of strategies to prevent polysubstance-impaired driving are lacking and urgently needed given the changing landscape of substance use and impaired driving. Additionally, given inequitable impacts on some populations (American Indian and Alaska Native [AIAN] communities, rural populations, etc.), research is needed to examine strategy effectiveness among different populations. This NOFO supports research that can help fill these gaps
Research may include, but is not limited to, evaluation of the impact of any of the following on preventing polysubstance-impaired driving and related outcomes:
This NOFO encourages examination of strategy effects on polysubstance-impaired driving and associated injuries and deaths among the overall population and disproportionately affected populations.
Additional Eligibility Category:
Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-056.html
RFA-DA-25-056
National Institutes of Health (NIH)
Current
Cooperative agreement
$1,900,000 (FY 2025)
One
Letter of Intent: October 13, 2024
Application: November 13, 2024
Earliest start date: July 2025
Up to five years
There is a lack of early translational funding and technical support for new product developers to move beyond the idea stage and into the product development space. Establishing a technical development center (or centers) will assist researchers developing new digital therapeutics for SUD. These centers will provide idea developers with technical development support to prepare the PI for future funding applications (e.g., Phase I SBIR, other NIH research grants, Blueprint Neurotherapeutics or Blueprint MedTech). The technical development assistance will include support from experts in the idea to product translation activities including the following: target product profile development clinical need assessment project plan development with timeline and milestones prototype development proof-of-concept study design preliminary safety assessments assistance in understanding current and future regulatory requirements.
Other Eligible Applicants include the following:
Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-085.html
RFA-DA-25-085
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Current
Cooperative agreement
$350,000 in direct costs; $500,000 total
One
Letter of intent: October 13, 2024
Application: November 13, 2024
Earliest start date: July 2025
Four years
The purpose of this concept is to facilitate the formation and maintenance of multidisciplinary research teams ready to employ epidemiological and/or etiological datasets and analyses to answer substance use prevention research questions and apply findings to intervention development or implementation. Projects supported through this concept will combine hands-on meeting formats, including both sandpit and hackathon approaches, with activities to sustain new research teams and networks, creating a foundational structure for research programs that have impact across disciplines
Other Eligible Applicants include the following:
NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-013.html
RFA-DA-23-013
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
Current
Grant
$2,000,000
Two
Letter of intent: October 14, 2022
Application: November 14, 2024
Earliest start date: July 2025
2025-2030; five years total
This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities in substance use, addiction, and related health consequences, including HIV. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability. As such, applications must be submitted by collaborative community partnered investigative teams who will conduct research projects that address issues prioritized by the relevant communities. No preliminary data are required. However, projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce desired outcomes.
Rigorous Evaluation of Primary and Secondary Overdose Prevention Activities Among Populations Disproportionately Affected by Overdose
https://apply07.grants.gov/apply/opportunities/instructions/PKG00287807-instructions.pdf
RFA-CE-25-149
Centers for Disease Control (CDC), Division of Overdose Prevention
Current
Cooperative agreement
Funding Option A: (three years total; will support research projects that support implementation and rigorous evaluation of prevention activities)
Funding Option B: (will support research projects that support development, implementation, and rigorous evaluation of prevention activities)
Seven
Letter of intent (optional): November 4, 2024
Application: December 2, 2024
August 29, 2025
Funding Option A:
Funding Option B:
This NOFO funds research focused on people experiencing disproportionate burden of drug overdose, those who are at greater risk of exposure to drug use, or those experiencing adverse drug use outcomes related to social determinants of health. Your research should rigorously evaluate either primary or secondary prevention strategies for reducing rates of nonfatal overdose, fatal overdose, and/or substance use disorders involving federally illegal drugs or misuse of prescription medications, drug use, or initiation of drug use, particularly among youth.
The following types of Higher Education Institutions are encouraged to apply for CDC support as Public or Private Institutions of Higher Education:
Effectiveness Research to Prevent Polysubstance-Impaired Driving
https://apply07.grants.gov/apply/opportunities/instructions/PKG00287806-instructions.pdf
RFA-CE-25-028
Centers for Disease Control and Prevention NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL
Current
Cooperative agreement
First budget period (September 30, 2025 to September 29, 2026): $350,000
Total period of performance (September 30, 2025 to September 29, 2028): $1,050,000
One (FY 2025)
Letter of Intent: November 1, 2024
Application: December 2, 2024
Pending award date
First budget period: September 30, 2025 to September 29, 2026
The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research to rigorously evaluate and examine effectiveness of strategies, programs, or policies (collectively referred to as “strategies”) for preventing polysubstance-impaired driving and associated crashes, nonfatal injuries, or deaths. Polysubstance-impaired driving means driving while impaired by two or more substances, such as alcohol and opioids or cannabis and alcohol. Comprehensive evaluations of strategies to prevent polysubstance-impaired driving are lacking and urgently needed given the changing landscape of substance use and impaired driving. Additionally, given inequitable impacts on some populations (American Indian and Alaska Native [AIAN] communities, rural populations, etc.), research is needed to examine strategy effectiveness among different populations. This NOFO supports research that can help fill these gaps.
Research may include, but is not limited to, evaluation of the impact of any of the following on preventing polysubstance-impaired driving and related outcomes:
This NOFO encourages examination of strategy effects on polysubstance-impaired driving and associated injuries and deaths among the overall population and disproportionately affected populations.
Additional Eligibility Category:
Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-050.html
RFA-DA-25-050
National Institutes of Health
Current
Grant
$2,000,000
Two to five (FY 2025)
December 2, 2024
By July 2025
Phase I: One year
Phase II: Three years
This notice of funding opportunity (NOFO) encourages Small Business Innovation Research (SBIR) grants applications from small business concerns (SBC) proposing research and development of solutions targeted to improve health outcomes and reduce the impact of adverse health consequences of non-disordered drug use. Solutions could be based on original technologies or existing technologies already available that could be repurposed to target the specific needs of people who use drugs. Proposed solutions should emphasize accessibility and affordability and be designed to be implemented in healthcare services.
Small businesses
Foreign components of non-domestic (non-U.S.) components of U.S. organizations, as defined in the NIH Grants Policy Statement, may be allowed.
Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-049.html
RFA-DA-25-049
National Institutes of Health
Current
Grant
$1,000,000
Two to three (FY 2025)
December 2, 2024
By July 2025
Phase I: One year
This funding opportunity calls for developing novel solutions targeted to improve health outcomes and reduce the impact of adverse health consequences in people who use drugs. These solutions should maximize accessibility and affordability, ideally designed to be implemented in mobile community-based care systems and able to reach the vulnerable and underserved population with limited engagement with conventional healthcare services. Solutions could be based on original technologies or existing technologies already available that could be repurposed to target the specific needs of people who use drugs.
Small businesses
Foreign components of non-domestic (non-U.S.) components of U.S. organizations, as defined in the NIH Grants Policy Statement, may be allowed.
Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) - Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-010.html
RFA-CA-25-010
National Institutes of Health
Current
Cooperative agreement
$2,400,000
Three (FY 2025)
December 6, 2024
Pending
Two years
This notice of funding opportunity (NOFO) invites proposals for research projects to advance the science of scale-up and sustainment of tobacco use treatment (TUT) for cancer survivors. Each research project will propose a trial to test implementation strategies to equitably and effectively scale-up and sustain the delivery of TUT to a large number of diverse clinical care delivery settings and cancer survivor populations, with an emphasis on cancer survivor populations experiencing health inequities.
Other Eligible Applicants include the following:
Spark Good Local Grants
https://www.walmart.org/how-we-give/program-guidelines/spark-good-local-grants-guidelines
N/A
Walmart
Current
Grant
$250 to $5,000
Unknown
November 1 to December 15, 2024
Refer to Spark Good Local Grants site for announcements of 2025 application periods.
Unknown
Unknown
Walmart believes that strengthening local communities creates value for business as well as society. Each year, Walmart U.S. stores, Sam's Clubs and Distribution Centers award local cash grants ranging from $250 to $5000. These local grants are designed to address the unique needs of the communities where we operate.
Spark Good Local Grants are awarded through an open application process to eligible organizations operating locally and directly benefiting the service area of the facility from when they are requesting funding.
All organizations interested in applying for a Spark Good Local Grant must have a Spark Good account on Walmart.com/nonprofits and be verified by Walmart's third-party verification partner, Deed. Only authorized users of the organization's Spark Good account may apply.
Organizations may only have a combined total number of 25 submitted and/or approved applications at any given one time for the calendar year, regardless of quarterly submission.
Final decisions on applications submitted within each quarter are made prior to the next quarter's application opening.
If approved, grant funds are distributed through electronic payment.
Organizations must have a Spark Good account and be verified by Deed, Walmart's third-party verification service provider.
If recommended for funding, the organization must provide electronic payment information to complete the approval process. All grants are disbursed through electronic payment.
Organizations applying must meet one of following criteria:
Non-charities, including organizations recognized as 501(c)(4)s, (c)(6)s, and (c)(19)s like homeowner's associations, civic leagues, or volunteer fire companies, are not eligible at this time.
Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)
https://grants.nih.gov/grants/guide/pa-files/PA-21-180.html
PA-21-180
National Institutes of Health
Current
R32 planning grant
Pending
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications
Jan 7, 2025
By July 2025
Three years
This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.
Other Eligible Applicants include the following:
Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Not Allowed)
https://grants.nih.gov/grants/guide/pa-files/PAR-22-039.html
PAR-22-039
National Institutes of Health
Current
R01 research grant
Pending
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Jan 7, 2025
By July 2025
The scope of the proposed project should determine the project period. The maximum project period is five years.
Reissue of PAR-18-942. The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement.
Other Eligible Applicants include the following:
Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)
https://grants.nih.gov/grants/guide/pa-files/PAR-23-095.html
PAR-23-095
National Institutes of Health
Current
R01 research grant
Pending
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Jan 7, 2025
Before April 2025
The scope of the proposed project should determine the project period. The maximum project period is five years.
The purpose of this funding announcement is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research.
Other Eligible Applicants include the following:
Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html
PAR-23-050
National Institutes of Health
Current
R01 research grant
Pending
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Jan 7, 2025
Before July 2025
The scope of the proposed project should determine the project period. The maximum project period is five years.
This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration.
Other Eligible Applicants include the following:
Youth Coalitions for Drug Demand Reduction
https://www.grants.gov/search-results-detail/356980
OFOP0001671
Bureau of International Narcotics-Law Enforcement
Current
Cooperative agreement
Minimum: $500,000
Maximum: $700,000
One
Jan 10, 2025
Before March 2025
36 months
INL announces open competition for organizations to submit proposals to carry out a project to improve youth engagement in drug demand reduction interventions, expanding access to community mental health services, and supporting drug prevention through school-based in underserved communities. The project should plan for implementation in at least 10 communities, including at least three communities each in Peru's coast, Andean, and Amazonian regions.
Disaster Recovery National Dislocated Worker Grants to Address the Opioid Crisis
https://www.grants.gov/search-results-detail/345349
ETA-TEGL-04-18
U.S. Department of Labor Employment and Training Administration
Current
Grant
$100,000,000
At its discretion, ETA will award opioid crisis Disaster Recovery DWGs to applicants who meet the requirements of this Training and Employment Guidance Letter (TEGL) until HHS' health emergency declaration expires.
Jan 3, 2025
To provide Disaster Recovery Dislocated Worker Grants (DWGs) to create disaster-relief employment as well as to provide employment and training activities, including supportive services, to address economic and workforce impacts related to widespread opioid use, addiction, and overdose.
Вавада-зеркало дает доступ к слотам. Vavada радует участников турниров крупными призами и бонусами.
